Background A history of brief intermittent social defeat stress can escalate cocaine self-administration and induce long-term adaptations in the mesolimbic dopamine system. Extrahypothalamic corticotrophin releasing factor (CRF) has been shown to be closely associated with stress-induced escalation of drug use. How repeated stress modulates CRF release in the ventral tegmental area (VTA) and the roles of CRF receptors during different phases of stress-induced cocaine selfadministration remain to be defined. Objective The current study examines the roles of CRF and CRF receptor 1 (CRFR1) in escalated intravenous cocaine self-administration after exposure to social defeat stress in mice.
Introduction
Exposure to stressful life events can profoundly increase the vulnerability to drug use in humans (Sinha 2001; Sinha 2008) . Evidence from preclinical studies also confirms that stressful events, such as mild foot shock, social defeat, and social isolation, lead to increased drug self-administration and drugseeking behavior (Bossert et al. 2013; Holly et al. 2016; Piazza and Le Moal 1998) . Studies investigating the neurobiological mechanisms by which stress influences drug selfadministration have mainly focused on the hypothalamicpituitary-adrenal axis, particularly the glucocorticoid receptors and corticotropin releasing factor (CRF) (Koob and Zorrilla 2010; Piazza and Le Moal 1998 ), yet how stress modulates CRF release and the roles of CRF during different phases of stress-escalated drug self-administration remain to be identified.
Stress stimulates CRF release from the hypothalamus, particularly from a subset of neurosecretory neurons with cell bodies in the paraventricular nucleus (PVN), and activates the hypothalamic-pituitary-adrenal axis, eventually increasing glucocorticoid secretion (Sarnyai et al. 2001 ). In addition, CRF is produced by neurons in extra-hypothalamic brain regions, such as the basolateral amygdala, the locus coeruleus, and the dorsal raphe nucleus (Cummings et al. 1983; Curtis et al. 1995; Snyder et al. 2012) . CRF release into the ventral tegmental area (VTA) after repeated stress and its long-lasting effects have received only sparse attention (Holly et al. 2016) .
The VTA has been implicated as a critical site of action for modulation of drug taking by social stress (Miczek et al. 2008; Miczek et al. 2011) . Intact dopaminergic cellular activity in the VTA is necessary for many motivated behaviors, including drug self-administration and drug seeking (Wise and Rompre 1989; Wise 1996) . The VTA is rich in dopamine-containing neurons that are a key site for direct and indirect CRFdopamine interactions (Borgland et al. 2010; Boyson et al. 2014 ; Korotkova et al. 2006; Wanat et al. 2008) . The release of CRF in the VTA is increased both during acute social stress and after repeated social defeat stress in rats (Holly et al. 2016) . Furthermore, the blockades of CRF receptor 1 (CRFR1) or receptor 2 (CRFR2) in the VTA have been found to prevent behavioral sensitization and escalated cocaine Bbinge^taking produced by social stress in rats (Boyson et al. 2011) . The evidence suggests that the VTA may be a critical brain region at which we can target to treat stressescalated cocaine taking.
CRF exerts its cellular effects by activating G-proteincoupled R1 and R2 (Hauger et al. 2006) , and these receptors are the targets for CRF antagonists. CRF has a much higher affinity for CRFR1 than CRFR2 (Vaughan et al. 1995) . Preclinical studies have shown that CRFR1 antagonists can also effectively block the escalation of drug selfadministration and aversive symptoms of drug withdrawal (Koob 2010) , as well as stress-induced reinstatement of drug seeking (Mantsch et al. 2016; Shaham et al. 1997) . The role of CRF in stress-escalated drug self-administration and seeking has been studied extensively (Holly et al. 2016; Shaham et al. 1997; Wang et al. 2005) ; nonetheless, how repeated social defeat stress influences VTA CRF release in mice and whether or not antagonism of CRF receptors can prevent and reverse the stress effects needs to be further characterized.
To characterize the neurobiological mechanisms through which psychosocial experiences alter cocaine use, we adopted a social defeat procedure that mimics the stressful experience in humans (Björkqvist 2001; Miczek et al. 2008) . We focus on a type of social stress that consists of intermittent episode of social defeat in brief confrontations with an aggressive resident mouse (Miczek et al. 1982; Yap and Miczek 2007) . To address the CRF mechanisms through which experience of social stress alters cocaine use, we first investigated whether pretreatment with a CRFR1 antagonist can block the social stress effects on cocaine self-administration in mice. After demonstrating prevention of stress-escalated drug intake, we then gave the drug prior to the cocaine self-administration to reverse the stress effects. Moreover, we added a CRF microdialysis experiment to directly measure CRF release in the VTA after repeated social defeat stress. Finally, we focused on the VTA as a key site of CRF action after repeated social defeat experience. Specifically, we microinjected a CRFR1 antagonist into the VTA and investigated the role of CRFR1 in the escalated cocaine self-administration in socially defeated mice.
Methods

Animals
Male Swiss Webster (CFW) mice (Charles River Laboratories; Wilmington, MA) weighing 23-25 g were singly housed under a reverse light/dark cycle (lights on from 6:00 p.m. to 6:00 a.m.) with ad libitum access to food and water. A separate group of adult male CFW mice was housed in pairs with females and served as aggressive stimulus residents. Before being used in these experiments, residents were screened to ensure the display of reliable aggressive behavior. All experimental procedures were approved by the Institutional Care and Use Committee (IACUC) of Tufts University and carried out in accordance with the NIH Guide for Care and Use of Laboratory Animals (National Research Council 2011).
Experimental design
The experimental design is depicted in Fig. 1 . In experiment 1 (Fig. 1(A) ), mice (n = 32) were randomly assigned to receive CRFR1 antagonist (CP 376,395) at a previously determined dose (15 mg/kg, i.p.) or saline 30 min before either intermittent social defeat stress or handling from day 1 to day 10. Six days later, mice were fitted with permanently indwelling jugular catheters for later cocaine selfadministration. In experiment 2, the procedure was similar, but mice (n = 26) received CP 376,395 pretreatment (5 and 15 mg/kg, i.p.) 10 min prior to each of two cocaine self-administration sessions (see Fig. 1(B) ). In addition, experiment 3 measured CRF in the VTA (n = 14) 10 days after the last episode of social defeat stress (see Fig. 1(C) ). Finally, experiment 4 evaluated the role of VTA CRFR1 after repeated social defeat stress on cocaine self-administration. As is shown in Fig. 1(D) , mice (n = 30) exposed for 10 days of social defeat stress or handling, subsequently were pretreated with intra-VTA CP 376,395 (0.5 and 1 μg/0.2 μl) prior to each of two cocaine selfadministration sessions.
Social defeat procedure
As previously described Miczek and O'Donnell 1978) , we used a resident-intruder paradigm for social defeat. Mice in the stressed groups were exposed to10 daily brief episodes of social defeats. Residents were used once daily and rotated through intruders so that intruders did not encounter the same resident more than once to avoid familiarity. The social defeat consisted of three phases. The first phase was termed instigation, in which the experimental animal was placed in a protective plastic cage inside the resident's home cage for 5 min, allowing unrestricted auditory, olfactory, and visual contact. The second phase was termed defeat, in which the intruder was removed from the perforated protective cage and was placed back into the resident's home cage for another 5 min or until the intruder received 30 attack bites. The third phase was termed threat, in which the intruder was then returned to the protective cage for another 5 min in the resident's home cage. During this last phase, intruders were still kept in a stressful environment, but without receiving further attack bites.
Intracranial surgery
Mice were anesthetized with a combination of ketamine (100 mg/kg, i.p.) and xylazine (10 mg/kg, i.p.). For the microdialysis experiment (experiment 3), a unilateral microdialysis cannula ( 
Microinjection
On test days, mice were given intra-VTA injections of vehicle (aCSF) or CRFR1 antagonist CP 376,395 (0.5-1.0 μg). Bilateral injections were delivered simultaneously in a volume of 0.2 μl per side at a flow rate of 0.1 μl/min into the VTA controlled by an automatic CMA/100 microinjection pump (CMA Microdialysis, Sweden). The injector needles were extended by 0.1 mm beyond the end of the guide cannulae (Plastics One, Roanoke, VA) and they were left in place for 1 min after the end of the infusion to allow diffusion and to prevent backflow. Microinjections occurred 10 min prior to the cocaine self-administration test.
Intravenous cocaine self-administration
Surgery Mice were implanted with permanently indwelling catheters (Silastic laboratory silicone tubing, Dow Corning, Midland, MI; ID 0.30 mm, OD 0.64 mm) into the right jugular vein under a combination of ketamine hydrochloride (100 mg/ mg i.p.) and xylazine (10 mg/mg i.p.) anesthesia. The catheter was tied to the vein with surgical silk and was passed subcutaneously to the back of the mouse where the catheter was affixed to a small plastic pedestal (Plastics One, Roanoke, were conducted daily for 10 days. All animals were catheterized 6 days after the last episode of defeat and were allowed to self-administer cocaine on day 20 (except experiment 3 (C)). In experiment 1 (A), mice were pretreated with CP 376,395 (15 mg/kg, i.p) 30 min prior to each defeat. In experiment 2 (B), mice were administered CP 376,395 (5 and VA). After the surgery, the catheters were flushed daily with heparin (30 IU/ml) to avoid clotting.
Acquisition Mice were allowed to freely self-administer cocaine (1.0 mg/kg/infusion). The custom apparatus used for cocaine self-administration was as described previously Yap and Miczek 2007) . A panel equipped with cue lights and two nose-poke operanda was inserted vertically into the home cage of the animal. Mice were reinforced for nose-poking the cue-paired (active) operandum by delivery of intravenous cocaine. A timeout period of 30 s followed each drug injection to avoid overdose. All responses were recorded automatically using a computer interface and software from Med Associates (St. Albans, VT, USA). Mice were trained to self-administer cocaine one session daily according a fixed ratio 1 (FR1) schedule. Each session lasted for a maximum of 2 h or until the mouse received 20 cocaine infusions. The acquisition was conducted for 5 days.
Cocaine self-administration After the acquisition, mice were subsequently tested under an FR1 schedule with 0.3 mg/kg/ infusion unit dose of cocaine, which was indicated as an optimal dosage to identify the stress effects on escalated cocaine intake in mice . In experiment 2, mice were pretreated with CP 376,395 (0, 5 and 15 mg/kg, i.p.) 10 min prior to cocaine self-administration test. In experiment 4, mice received intra-VTA CRFR1 antagonist (0, 0.5, and 1 μg/ 0.2 μl) prior to the mice being given access to cocaine. The drug doses were injected in a counterbalanced within-subjects design prior to each 2-h cocaine self-administration daily session.
In vivo CRF microdialysis
In vivo microdialysis occurred 10 days after the last episode of the social defeat as described above. On the night before the microdialysis experiment, the guide cannula cap was removed and replaced with a microdialysis probe (1 mm active membrane, Synaptech Inc., Marquette, MI), which was perfused with an artificial cerebrospinal fluid (aCSF, 147 mM NaCl, 2.8 mM KCl, 1.2 mM CaCl 2 , 1.2 mM MgCl 2 ) at a flow rate of 0.5 μl/min overnight. The following morning, aCSF was replaced with aCSF containing 0.2% bovine serum albumin (BSA) and the flow rate increased to 2.0 μl/min 2 hours prior to sample collection. Samples were collected by hand into Eppendorf Protein LoBind tubes every 15 min and immediately stored at −80°C. Tonic levels of CRF were measured in five baseline samples before experimental manipulations. Then, seven more samples were collected to evaluate the time course of CRF changes after a cocaine challenge (10 mg/kg, i.p.).
CRF was quantified by a commercially available enzyme immunoassay (EIA kit, Peninsula Laboratories, San Carlos, CA). Standards were diluted with aCSF 0.2% BSA rather than the provided standard diluent buffer to make sure standards and samples were treated equally. All other steps were identical to the recommended EIA protocol.
Histology
After the completion of the self-administration or dialysis experiment, mice were deeply anesthetized with an overdose of ketamine and xylazine combination and underwent transcardial perfusion with 0.9% saline and 4% paraformaldehyde (PFA). Brain tissue was preserved in 4% PFA and then sectioned in 50-μm slices using a cryostat (Leica CM1900, Bannockburn, IL). The brain sections were mounted on gelatin-coated slides and stained with cresyl violet, and the cannula placements were verified by light microscopy, according to the mouse brain atlas (Paxinos and Franklin 2001).
Drugs
Cocaine hydrochloride was obtained from the National Institute on Drug Abuse through the drug supply program (Rockville, MD). It was dissolved in sterile 0.9% saline solution (0.6 and 2.0 mg/ml). Cocaine was self-administered intravenously based on each animal's body weight. CP 376, 395 is a selective CRFR1 antagonist (Ki values are 12 and >10,000 nM for CRFR1 and CRFR2, respectively) and it can dissolve easily in an aqueous solution. For systemic injection, CP-376, 395 was dissolved in sterile 0.9% saline (5 and 15 mg/kg i.p.) at a volume of 0.1 ml/kg body weight. For microinjection, it was freshly suspended in aCSF immediately before microinjections (0.5 and 1 μg/0.2 μl).
Statistical analysis
Data analyses were performed using Sigma Stat Version 13.0 (Systat Software Inc., San Jose, CA, USA). To assess the effects of pretreatment with CRFR1 antagonist (systemic injection) prior to social stress on cocaine self-administration and the effects of CRFR1 (systemic injection) after social stress on cocaine self-administration, data were analyzed with a two-way ANOVA. To analyze the effects of microinjection of the CRFR1 antagonist into the VTA after repeated stress, the numbers of cocaine infusions were assessed with a twoway repeated ANOVA with group (stressed or nonstressed control) as the between-subject factor and the drug dosage as the within-subject factor. For CRF microdialysis, data were also analyzed with a two-way repeated ANOVA. All post hoc comparisons were performed with Bonferroni tests. Data are presented as mean ± SEM. The criterion for statistical significance was p < 0.05.
Results
Experiment 1: pharmacological blockade of CRFR1 prevents the effects of stress on cocaine intake
Of the original 32 mice, two mice died during surgery. Two mice were removed due to catheter failure. CRFR1 antagonist (15 mg/kg, i.p.) given before each episode of social defeat stress did not change the animals' reactions during social defeat stress. Neither stress nor CRFR1 antagonist influenced nose-poking responses (see Fig. 2 ) or the average number of infusions (data were not shown) during acquisition phase.
CRFR1 antagonism (CP 376,395, 15 mg/kg, i.p.) given 30 min prior to each social defeat episode prevented subsequent escalation of cocaine self-administration. Overall, two-way ANOVA revealed a significant stress effect (F 1, 27 = 7.30; p < 0.05), a significant drug treatment effect (F 1, 27 = 4.99; p < 0.05), and a significant interaction effect between stress and drug treatment (F 1, 27 = 2.58; p < 0.05). As shown in Fig. 2 , post hoc analysis revealed that repeated social defeat stress-escalated cocaine selfadministration relative to nonstressed controls under saline conditions (t 12 = 3.46; p < 0.05). Pretreatment with the CRFR1 antagonist CP 376,395 (15 mg/kg, i.p.) prior to each episode of social defeat stress prevented the effects of social defeat on later cocaine self-administration (t 13 = 3.24; p < 0.05). In addition, CRFR1 antagonist did not alter cocaine self-administration in control groups. Although several studies have demonstrated that CRFR1 antagonists can decrease cocaine intake in rats (Goeders and Guerin 2000) , the lack of effects in the current experiment could be due to the difference in species.
Experiment 2: pharmacological blockade of CRFR1 reverses stress-escalated cocaine self-administration Three mice were excluded from the results because of catheter patency issues. Repeated social defeat stress did not alter the pattern of cocaine self-administration during acquisition phase (data are not shown).
CRFR1 antagonist (CP 376,395) given immediately before each self-administration session dose-dependently reversed the long-term effects of social defeat stress on cocaine taking. Overall, there was a significant drug treatment effect (F 3, 73 = 5.82; p < 0.01), and a significant interaction effect between stress and drug treatment (F 3, 73 = 4.10; p < 0.05), but no significant stress effect (F 1, 73 = 3.03; p = 0.096). As shown in Fig. 3 , post hoc analysis revealed that repeated social defeat stress-escalated cocaine self-administration relative to nonstressed saline treated controls (t 22 = 2.85; p < 0.05). High-dose but not low-dose CP 376,395 significantly reduced cocaine self-administration in mice that underwent prior social defeat but not on non-defeated mice (t 11 = 3.89; p < 0.05).
Experiment 3: repeated social defeat stress increased CRF release in the VTA Schematic representations of probe placements in the VTA and a representative Nissl-stained section showing the location of the probe are presented in Fig. 4 (two mice with incorrect placement and two mice that chewed the tubing during sample collections were excluded from the data analysis).
Overall, repeated social defeat stress elevated the basal level of CRF in the VTA and also resulted in greater increases in CRF after cocaine injection. The averages of first four samples in each mouse served as a CRF baseline measurement. A t test revealed a significant increase compared to the control group in mice that underwent social defeat (t 9 = −3.65; p < 0.05 see Fig. 4) . Thereafter, the stress-experienced and the nonstressed controls were challenged with a 10 mg/kg cocaine injection. A two-way repeated ANOVA analysis revealed a significant time effect (F 8, 89 = 2.91; p < 0.01); however, neither stress (F 1, 89 = 2.68; p = 0.14) nor the interaction between stress and time (F 8, 89 = 0.97; p = 0.47) showed a significant role in VTA CRF release. Interestingly, mice with a history of defeat showed a higher CRF release in the VTA immediately after Another two mice with catheter failure were also excluded from the results. To further explore the role of CRFR1, CP 376,395 (0.5 and 1 μg/0.2 μl) was infused directly into the VTA before the cocaine self-administration session. Intra-VTA CP 376,395 dose-dependently reversed the long-term effects of stressescalated cocaine self-administration. A two-way repeated ANOVA revealed a significant effect of stress on cocaine taking (F 1, 99 = 7.63; p < 0.05), a significant drug treatment effect (F 3, 99 = 2.83; p < 0.05), and a significant interaction between stress and drug treatment (F 3, 99 = 4.11; p < 0.05). As shown in Fig. 5 , post hoc analysis revealed that under aCSF conditions, repeated social defeat stress increased cocaine selfadministration compared to nonstressed controls (t 24 = 2.81; p < 0.05). Pretreatment with the higher dose of CP 376,395 (1 μg/0.2 μl/side), but not the lower dose (0.5 μg/0.2 μl/side), reversed the stress-escalated cocaine intake (t 11 = 4.31; p < 0.05).
Discussion
The current experiments demonstrate that repeated episodes of social defeat stress can result in long-lasting increased CRF release in the VTA. Moreover, the results suggest that CRFR1 exerts multiple roles during the initial reaction to social stress and during long-term neuroadaptations that are relevant to escalated cocaine taking. Antagonism of CRFR1 has proven effective in preventing and reversing social stress effects on cocaine self-administration and reinstatement. Our study shows reversal of stress-escalated cocaine intake long after the stress experience; both systemic and intra-VTA CP 376,395 dose-dependently block social stress effects when given prior to cocaine self-administration. In agreement with previous studies (Boyson et al. 2011; Han et al. 2015; Miczek et al. 2011) , the current findings demonstrate that social defeat stress escalates cocaine selfadministration in mice. Despite substantial differences in social defeat stress protocols, durations of cocaine selfadministration access, strains and species, most studies indicate that brief episodes of intermittent social defeat stress reliably escalate cocaine self-administration and seeking (Covington and Miczek 2001; Manvich et al. 2016; Quadros and Miczek 2009) .
Control
Different kinds of stressors result in CRF release and CRF receptor activation in extra-hypothalamic pathways (Holmes et al. 2003) . CRF-like immunoreactivity has been identified in the neocortex, extended amygdala, medial septum, hypothalamus, thalamus, cerebellum, and autonomic midbrain and hindbrain nuclei (Charlton et al. 1987; Swanson et al. 1983) . Recent studies have drawn more attention to CRF signaling in the VTA after stress exposure. For example, Wang et al. (2005) demonstrated that acute foot shock stress (0.3-0.6 mA) increases CRF release within the VTA in rats. However, the nature of CRF release in the VTA during acute and repeated social defeat stress, as well as its role in enduring neuroadaptations driving later drug taking and seeking, is still poorly understood. The present results show that repeated social defeat stress results in escalated CRF basal levels in the VTA in mice, suggesting that long-lasting changes in VTA CRF after repeated social defeat stress may be critical for stress-escalated cocaine self-administration.
A recent study from our laboratory has shown that CRF release during social defeat stress may contribute to later escalated cocaine taking, and that persistently elevated CRF tone in the VTA may drive later cocaine seeking in rats (Holly et al. 2016) . The current study confirms and extends the findings that repeated social defeat stress elevates CRF tone in the VTA, which may contribute to later stressescalated cocaine self-administration in mice. Together, these findings suggest that CRF in the VTA may underlie the fundamental link between social stress and escalated cocaine selfadministration in rodents. In addition, the present study demonstrates that repeated social defeat stress results in a sensitized CRF overflow in the VTA after a cocaine challenge in mice, which is consistent with previous findings (Richter et al. 1995) that CRF is increased in the central amygdaloid nucleus after a cocaine challenge.
The roles of CRFR1 and CRFR2 in stress-induced drug self-administration and seeking are not consistent in the literature. Some studies have demonstrated that CRFR1 is more relevant than CRFR2 for foot shock-induced reinstatement of cocaine seeking (Blacktop et al. 2011; Koob 2010) , while others suggest that both CRFR1 and CRFR2 are involved in social stress-escalated cocaine self-administration (Boyson et al. 2014) . The current study confirms and extends the role of CRFR1 in social defeat stress-escalated cocaine selfadministration in mice. Although previous studies have explored the roles of CRF receptor antagonists in preventing social defeat stress-induced cocaine self-administration in rats (Boyson et al. 2011; Boyson et al. 2014) , the current work focuses on how to reverse escalated cocaine selfadministration after repeated social defeat stress experience. To our knowledge, this is the first study showing that several weeks after exposure to repeated social defeat stress, systemic injection or VTA microinjection of a CRFR1 antagonist prior
Control Stress
Cocaine Infusions/2-h session to cocaine self-administration reversed stress-escalated cocaine self-administration in mice. Whether CRFR2 also plays a role in social defeat stress-escalated cocaine selfadministration in mice remains to be determined. Our findings suggest that brain penetrant CRFR1 antagonists may have therapeutic potential for stress-escalated cocaine taking. Although a substantial number of preclinical studies have demonstrated consistent effects of CRFR1 blockade on drug self-administration and drug seeking particularly in dependent individuals (Heilig and Koob 2007; Mantsch et al. 2016; Shaham et al. 1997; Zorrilla et al. 2013) , two recent clinical studies show negative outcomes with CRFR1 antagonists treatment in alcoholics (Kwako et al. 2015; Schwandt et al. 2016) . Why do the CRFR1 antagonists fail in the translation from preclinical to clinical research? One potential reason is that preclinical research has not yet captured essential features of human addiction. In addition, the human laboratory model and the laboratory animal model may differ in terms of evaluating efficacy of the drugs. Lastly, the two clinical studies with negative findings deals with alcoholic patients. So far, there are still no clinical studies evaluating the effects of CRFR1 antagonists in psychostimulant or opiate use disorders (Shaham and de Wit 2016) . Particularly, whether CRFR1 antagonists can block stress-escalated drug taking or seeking requires further verifications in clinical research.
In summary, the present experiments confirm and extend the roles of CRFR1 in stress-escalated cocaine self-administration, indicating that CRFR1 can be a target for either preventing or reversing stress effects. Importantly, we demonstrate that CRF within the VTA is increased after repeated social defeat stress, which may be responsible for the subsequent escalated cocaine self-administration. The current study starts to explore CRF-dopamine interactions by targeting CRF receptors in one of the key sources of dopamine, namely the VTA. For future studies, the precise interactions of CRF and dopamine systems need to be further investigated by targeting the specific CRF and dopaminergic neurons, using optogenetic or chemogenetic approaches.
